American Association for Cancer Research
crc-22-0478-s11.png (167.93 kB)

Supplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway

Download (167.93 kB)
posted on 2023-08-18, 14:20 authored by Inyoung Lee, Miriam Doepner, Jillian Weissenrieder, Ariana D. Majer, Sophia Mercado, Angela Estell, Christopher A. Natale, Pamela J. Sung, J. Kevin Foskett, Martin P. Carroll, Todd W. Ridky

Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.


HHS | NIH | National Cancer Institute (NCI)



Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.